Jump to content

Rapastinel

From Wikipedia, the free encyclopedia
Rapastinel
Clinical data
Other namesGLYX-13; BV-102
Routes of
administration		Intravenous
Drug classSelective NMDA receptor modulator
ATC code
  • None
Legal status
Legal status
Identifiers
  • (S)-N-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-1-[(S)-1-((2S,3R)-2-amino-3-hydroxybutanoyl)pyrrolidine-2-carbonyl]pyrrolidine-2-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC18H31N5O6
Molar mass413.475 g·mol−1
3D model (JSmol)
  • C[C@H]([C@@H](C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)N)N)O
  • InChI=1S/C18H31N5O6/c1-9(24)13(19)18(29)23-8-4-6-12(23)17(28)22-7-3-5-11(22)16(27)21-14(10(2)25)15(20)26/h9-14,24-25H,3-8,19H2,1-2H3,(H2,20,26)(H,21,27)/t9-,10-,11+,12+,13+,14+/m1/s1
  • Key:GIBQQARAXHVEGD-BSOLPCOYSA-N

Rapastinel (INNTooltip International Nonproprietary Name) (former developmental code name GLYX-13) is a novel antidepressant that was under development by Allergan (previously Naurex) as an adjunctive therapy for the treatment of treatment-resistant depression.[1][2] It is a centrally active, intravenously administered (non-orally active) amidated tetrapeptide that acts as a novel and selective modulator of the NMDA receptor.[1][2][3] The drug is a rapid-acting and long-lasting antidepressant as well as robust cognitive enhancer by virtue of its ability to enhance NMDA receptor-mediated signal transduction and synaptic plasticity.[1][2][3]

Clinical development

[edit]

On March 3, 2014, the U.S. FDA granted Fast Track designation to the development of rapastinel as an adjunctive therapy in treatment-resistant major depressive disorder.[4] As of 2015, the drug had completed phase II clinical development for this indication and achieved proof of concept as a rapid-acting antidepressant by demonstrating reduced depressive symptoms at days 1 through 7, as assessed by the HAM-D, without eliciting psychotomimetic or other significant side effects.[5] On January 29, 2016, Allergan (who acquired Naurex in July 2015) announced that rapastinel had received Breakthrough Therapy designation from the U.S. FDA for adjunctive treatment of major depressive disorder.[6]

On March 6, 2019, Allergan announced rapastinel failed to differentiate from placebo during phase III trials.[7] Early successful clinical studies of rapastinel in depression spurred the development of next-generation compounds with similar mechanisms of action including apimostinel (GATE-202, NRX-1074), a 2nd generation analog with improved potency, and zelquistinel (GATE-251, AGN-241751), a 3rd generation small molecule with improved potency and high oral bioavailability.[8]

Preclinical development

[edit]

Rapastinel was originally invented by Joseph Moskal, the co-founder of Naurex, via structural modification of B6B21, a monoclonal antibody that similarly binds to and modulates the NMDA receptor.[2][9][10][11] Rapastinel binds to a novel and unique domain on the NMDA receptor complex that is distinct from the glycine co-agonist binding site.[3][12] Rapastinel exhibits a biphasic dose response in vitro.[3][13] At therapeutically relevant concentrations, rapastinel enhances glutamate-mediated NMDA receptor activity, independent of glycine co-agonism, and enhances the magnitude of NMDAR-mediated synaptic plasticity at excitatory synapses in the mPFC.[3][13] Positive modulation of NMDA receptors by rapastinel produces antidepressant effects that are convergent with the NMDA receptor antagonist ketamine, however, rapastinel has no ketamine-like side effects such as cognitive impairment and psychotomimetic symptoms.[14][15]

In addition to its rapid and sustained antidepressant effects, rapastinel has been shown to enhance memory and learning in both young adult and learning-impaired, aging rat models.[16] It has been shown to increase Schaffer collateral-CA1 long-term potentiation in vitro. In concert with a learning task, rapastinel has also been shown to elevate gene expression of hippocampal NR1, a subunit of the NMDA receptor, in three-month-old rats.[17] Neuroprotective effects have also been demonstrated in Mongolian Gerbils by delaying the death of CA1, CA3, and dentate gyrus pyramidal neurons under glucose and oxygen-deprived conditions.[18]

See also

[edit]

References

[edit]
  1. ^ a b c Henter ID, Park LT, Zarate CA (May 2021). "Novel Glutamatergic Modulators for the Treatment of Mood Disorders: Current Status". CNS Drugs. 35 (5): 527–543. doi:10.1007/s40263-021-00816-x. PMC 8201267. PMID 33904154.
  2. ^ a b c d Moskal JR, Burgdorf JS, Stanton PK, Kroes RA, Disterhoft JF, Burch RM, Khan MA (2016). "The Development of Rapastinel (Formerly GLYX-13); A Rapid Acting and Long Lasting Antidepressant". Current Neuropharmacology. 15 (1): 47–56. doi:10.2174/1570159x14666160321122703. PMC 5327451. PMID 26997507.
  3. ^ a b c d e Donello JE, Banerjee P, Li YX, Guo YX, Yoshitake T, Zhang XL, et al. (March 2019). "Positive N-Methyl-D-Aspartate Receptor Modulation by Rapastinel Promotes Rapid and Sustained Antidepressant-Like Effects". The International Journal of Neuropsychopharmacology. 22 (3): 247–259. doi:10.1093/ijnp/pyy101. PMC 6403082. PMID 30544218.
  4. ^ "FDA Grants Fast Track Designation to Naurex's Rapid-Acting Novel Antidepressant GLYX-13" (Press release) – via www.prnewswire.com.
  5. ^ Preskorn S, Macaluso M, Mehra DO, Zammit G, Moskal JR, Burch RM (March 2015). "Randomized proof of concept trial of GLYX-13, an N-methyl-D-aspartate receptor glycine site partial agonist, in major depressive disorder nonresponsive to a previous antidepressant agent". Journal of Psychiatric Practice. 21 (2): 140–149. doi:10.1097/01.pra.0000462606.17725.93. PMID 25782764. S2CID 36800194.
  6. ^ "Allergan's Rapastinel Receives FDA Breakthrough Therapy Designation for Adjunctive Treatment of Major Depressive Disorder (MDD)". www.prnewswire.com (Press release). Retrieved 2022-05-13.
  7. ^ "Allergan Announces Phase 3 Results for Rapastinel as an Adjunctive Treatment of Major Depressive Disorder (MDD)". Archived from the original on June 22, 2023.
  8. ^ "Home - Gate Neurosciences". Archived from the original on 2023-09-05. Retrieved 2022-05-13.
  9. ^ Haring R, Stanton PK, Scheideler MA, Moskal JR (July 1991). "Glycine-like modulation of N-methyl-D-aspartate receptors by a monoclonal antibody that enhances long-term potentiation". Journal of Neurochemistry. 57 (1): 323–332. doi:10.1111/j.1471-4159.1991.tb02131.x. PMID 1828831. S2CID 37941813.
  10. ^ Moskal JR, Kuo AG, Weiss C, Wood PL, O'Connor Hanson A, Kelso S, et al. (December 2005). "GLYX-13: a monoclonal antibody-derived peptide that acts as an N-methyl-D-aspartate receptor modulator". Neuropharmacology. 49 (7): 1077–1087. doi:10.1016/j.neuropharm.2005.06.006. PMID 16051282. S2CID 7372648.
  11. ^ Burgdorf J, Zhang XL, Weiss C, Matthews E, Disterhoft JF, Stanton PK, Moskal JR (April 2011). "The N-methyl-D-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats". Neurobiology of Aging. 32 (4): 698–706. doi:10.1016/j.neurobiolaging.2009.04.012. PMC 3035742. PMID 19446371.
  12. ^ Pothula S, Liu RJ, Wu M, Sliby AN, Picciotto MR, Banerjee P, Duman RS (March 2021). "Positive modulation of NMDA receptors by AGN-241751 exerts rapid antidepressant-like effects via excitatory neurons". Neuropsychopharmacology. 46 (4): 799–808. doi:10.1038/s41386-020-00882-7. PMC 8027594. PMID 33059355.
  13. ^ a b Zhang XL, Sullivan JA, Moskal JR, Stanton PK (December 2008). "A NMDA receptor glycine site partial agonist, GLYX-13, simultaneously enhances LTP and reduces LTD at Schaffer collateral-CA1 synapses in hippocampus". Neuropharmacology. 55 (7): 1238–1250. doi:10.1016/j.neuropharm.2008.08.018. PMC 2661239. PMID 18796308.
  14. ^ Pothula S, Kato T, Liu RJ, Wu M, Gerhard D, Shinohara R, et al. (September 2021). "Cell-type specific modulation of NMDA receptors triggers antidepressant actions". Molecular Psychiatry. 26 (9): 5097–5111. doi:10.1038/s41380-020-0796-3. PMID 32488125. S2CID 219175373.
  15. ^ Kato T, Duman RS (January 2020). "Rapastinel, a novel glutamatergic agent with ketamine-like antidepressant actions: Convergent mechanisms". Pharmacology, Biochemistry, and Behavior. 188: 172827. doi:10.1016/j.pbb.2019.172827. PMID 31733218. S2CID 207976034.
  16. ^ Burgdorf J, Zhang XL, Weiss C, Matthews E, Disterhoft JF, Stanton PK, Moskal JR (April 2011). "The N-methyl-D-aspartate receptor modulator GLYX-13 enhances learning and memory, in young adult and learning impaired aging rats". Neurobiology of Aging. 32 (4): 698–706. doi:10.1016/j.neurobiolaging.2009.04.012. PMC 3035742. PMID 19446371.
  17. ^ Moskal JR, Kuo AG, Weiss C, Wood PL, O'Connor Hanson A, Kelso S, et al. (December 2005). "GLYX-13: a monoclonal antibody-derived peptide that acts as an N-methyl-D-aspartate receptor modulator". Neuropharmacology. 49 (7): 1077–1087. doi:10.1016/j.neuropharm.2005.06.006. PMID 16051282. S2CID 7372648.
  18. ^ Stanton PK, Potter PE, Aguilar J, Decandia M, Moskal JR (August 2009). "Neuroprotection by a novel NMDAR functional glycine site partial agonist, GLYX-13". NeuroReport. 20 (13): 1193–1197. doi:10.1097/WNR.0b013e32832f5130. PMID 19623090. S2CID 6269255.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Rapastinel&oldid=1199041309"